AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22722614 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 79
Study 22722614 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 79
Study 22722614 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS vs Exercise
Number of subjects: 79
Study 22722614 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS vs Acetaminophen
Number of subjects: 79
Study 20376002 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant (doses of 400 mg and above)
Number of subjects: 70
Study 20376002 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem (10 mg)
Number of subjects: 70
Study 20376002 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant (500 mg)
Number of subjects: 70
Study 20376002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 18990679 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior mandibular repositioning splints
Number of subjects: 34
Study 18990679 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated adults)
Number of subjects: 34
Study 15663704 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention
Number of subjects: 7
Study 15663704 — intervention group
Group type: COMPARATOR
Intervention: Local control practices
Number of subjects: 7
Study 15663704 — intervention group
Group type: COMPARATOR
Intervention: Distant control practices
Number of subjects: 7
Study 15663704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 7
Study 12190961 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised oestradiol (E2) 2 mg daily (n = 16)
Number of subjects: 60
Study 12190961 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HRT (2 mg E2 daily with trimegestone 0.5 mg daily or dydrogesterone 10 mg daily) (n = 28)
Number of subjects: 60
Study 12190961 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 60
Study 10208189 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (albuterol 10 mg/h plus ipratropium bromide 1.0 mg/h)
Number of subjects: 67
Study 10208189 — intervention group
Group type: COMPARATOR
Intervention: Albuterol alone (control)
Number of subjects: 67
Study 8544658 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS patients
Number of subjects: 30
Study 8544658 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study 2132343 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (D)
Number of subjects: 36
Study 2132343 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 36
Study 2132343 — intervention group
Group type: COMPARATOR
Intervention: Dopamine-nitroprusside (DN)
Number of subjects: 36
Study 649240 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of papaverine
Number of subjects: 19
Study 649240 — intervention group
Group type: COMPARATOR
Intervention: 1.0 ml of physiological saline (placebo)
Number of subjects: 19
Study 31084442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive theory-based intervention (CDT)
Number of subjects: 79
Study 31084442 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (Control)
Number of subjects: 79
Study 27884664 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle technique
Number of subjects: 110
Study 27884664 — intervention group
Group type: COMPARATOR
Intervention: Tray technique
Number of subjects: 110
Study 25926298 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipoint transcutaneous electrical acupuncture stimulation (TEAS)
Number of subjects: 92
Study 25926298 — intervention group
Group type: COMPARATOR
Intervention: Sham TEAS
Number of subjects: 92
Study 24412249 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom foot orthotics with limited chiropractic care
Number of subjects: 0
Study 24412249 — intervention group
Group type: COMPARATOR
Intervention: Flat insole sham with limited chiropractic care
Number of subjects: 0
Study 21181706 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanofill composite (Filtek Z350)
Number of subjects: 41
Study 21181706 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanohybrid composite (Esthet‐X)
Number of subjects: 41
Study 21181706 — intervention group
Group type: COMPARATOR
Intervention: Microhybrid composite (Filtek Z250)
Number of subjects: 41
Study 19129268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lone mothers
Number of subjects: 464
Study 19129268 — intervention group
Group type: COMPARATOR
Intervention: Married/partnered mothers
Number of subjects: 464
Study 17448700 — intervention group
Group type: EXPERIMENTAL
Intervention: diacerein 100mg/day
Number of subjects: 171
Study 17448700 — intervention group
Group type: COMPARATOR
Intervention: piroxicam 20mg/day
Number of subjects: 171
Study 17448700 — intervention group
Group type: EXPERIMENTAL
Intervention: diacerein
Number of subjects: 171
Study 17448700 — intervention group
Group type: COMPARATOR
Intervention: piroxicam
Number of subjects: 171
Study 15666492 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (300 mg/die)
Number of subjects: 2
Study 15666492 — intervention group
Group type: COMPARATOR
Intervention: Chlortalidone (50 mg/die)
Number of subjects: 2
Study 12495257 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 5 mg riboflavin (group IFR)
Number of subjects: 103
Study 12495257 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 2.75 mg retinyl palmitate (equal to 5000 IU vitamin A) (group IFA)
Number of subjects: 103
Study 12495257 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 5 mg riboflavin + 2.75 mg retinyl palmitate (group IFRA)
Number of subjects: 103
Study 12495257 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folate tablets (200 mg FeSO4 and 250 microg folic acid) + 5 mg glucose (group IF)
Number of subjects: 103
Study 10333395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic infection
Number of subjects: 37
Study 10333395 — intervention group
Group type: COMPARATOR
Intervention: No intra-amniotic infection
Number of subjects: 37
Study 8595510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 3TC (300 mg b.i.d.) plus AZT (200 mg t.i.d.) for 24 weeks
Number of subjects: 0
Study 8595510 — intervention group
Group type: COMPARATOR
Intervention: AZT monotherapy (200 mg t.i.d.)
Number of subjects: 0
Study 8595510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 3TC (300 mg b.i.d.) plus AZT (200 mg t.i.d.)
Number of subjects: 0
Study 8595510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 3TC (150 mg b.i.d.) plus AZT (200 mg t.i.d.)
Number of subjects: 0
Study 8595510 — intervention group
Group type: COMPARATOR
Intervention: AZT monotherapy (200 mg t.i.d. plus placebo)
Number of subjects: 0
Study 8595510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with AZT and 3TC
Number of subjects: 0
Study 2651031 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 10
Study 2651031 — intervention group
Group type: COMPARATOR
Intervention: Multiple injection technique (MIT)
Number of subjects: 10
Study 2651031 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 10
Study 345888 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental control (rigidly controlled, relatively fume‐ and particle‐free environment)
Number of subjects: 12
Study 28847751 — intervention group
Group type: EXPERIMENTAL
Intervention: GED‐0301 (160 mg/day) for 4 weeks
Number of subjects: 63
Study 28847751 — intervention group
Group type: EXPERIMENTAL
Intervention: GED‐0301 (160 mg/day) for 8 weeks
Number of subjects: 63
Study 28847751 — intervention group
Group type: EXPERIMENTAL
Intervention: GED‐0301 (160 mg/day) for 12 weeks
Number of subjects: 63
Study 28847751 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic improvement at week 12
Number of subjects: 63
Study 27306435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (SB)
Number of subjects: 4169
Study 27306435 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity physical activity (LPA)
Number of subjects: 4169
Study 27306435 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate- to vigorous-intensity physical activity (MVPA)
Number of subjects: 4169
Study 27306435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 4169
Study 24769270 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring
Number of subjects: 204
Study 24769270 — intervention group
Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 204
Study 22042908 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip protectors
Number of subjects: 116
Study 20923694 — intervention group
Group type: EXPERIMENTAL
Intervention: Right prefrontal HF‐rTMS
Number of subjects: 0
Study 20923694 — intervention group
Group type: EXPERIMENTAL
Intervention: Left prefrontal HF‐rTMS
Number of subjects: 0
Study 18404609 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 156
Study 18404609 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 156
Study 16162741 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-ifosfamide-cisplatin followed by surgery
Number of subjects: 167
Study 16162741 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 167
Study 11920488 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (40 mg genistein per day)
Number of subjects: 68
Study 11920488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 10798812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 22
Study 10798812 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 8844237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 20
Study 8844237 — intervention group
Group type: COMPARATOR
Intervention: Atracurium
Number of subjects: 20
Study 9259823 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 CPD‐A2 RCC
Number of subjects: 49
Study 9259823 — intervention group
Group type: COMPARATOR
Intervention: CPD‐A1 RCC
Number of subjects: 49
Study 6669927 — intervention group
Group type: EXPERIMENTAL
Intervention: Instilled fluid volumes of 2.5, 5, 10, and 15 ml at pH 1.0, 4.0, or 7.0
Number of subjects: 8
Study 6669927 — intervention group
Group type: EXPERIMENTAL
Intervention: Instilled fluid at low pH (1.0)
Number of subjects: 8
Study 31843854 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthTracker-based structured medication review tool
Number of subjects: 79
Study 30339644 — intervention group
Group type: EXPERIMENTAL
Intervention: PC‐PALs
Number of subjects: 190
Study 30339644 — intervention group
Group type: COMPARATOR
Intervention: GP‐PALs
Number of subjects: 190
Study 26332775 — intervention group
Group type: EXPERIMENTAL
Intervention: 105RM
Number of subjects: 14
Study 26332775 — intervention group
Group type: EXPERIMENTAL
Intervention: 125RM
Number of subjects: 14
Study 26332775 — intervention group
Group type: COMPARATOR
Intervention: 0RM
Number of subjects: 14
Study 26252038 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior meatal antrostomy
Number of subjects: 44
Study 26252038 — intervention group
Group type: COMPARATOR
Intervention: No inferior meatal antrostomy (control group)
Number of subjects: 44
Study 22565284 — intervention group
Group type: EXPERIMENTAL
Intervention: CCCL ALL protocol (risk-adapted therapy)
Number of subjects: 111
Study 20128938 — intervention group
Group type: EXPERIMENTAL
Intervention: diet/probiotics
Number of subjects: 256
Study 20128938 — intervention group
Group type: COMPARATOR
Intervention: diet/placebo
Number of subjects: 256
Study 20128938 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 256
Study 20128938 — intervention group
Group type: EXPERIMENTAL
Intervention: diet intervention
Number of subjects: 256
Study 18926146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac contractility modulation (CCM)
Number of subjects: 0
Study 18926146 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15743283 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility exercise group (n=30)
Number of subjects: 61
Study 15743283 — intervention group
Group type: COMPARATOR
Intervention: Stretching/weight-shifting exercise group (n=31)
Number of subjects: 61
Study 15743283 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Agility and Stretching/weight-shifting)
Number of subjects: 61
Study 11924899 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment
Number of subjects: 27
Study 11924899 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 27
Study 10090111 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 1292
Study 10090111 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 1292
Study 10090111 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, Clonidine, Atenolol
Number of subjects: 1292
Study 10090111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1292
Study 7750020 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (100 IU/day i.m. plus 500 mg of elemental calcium for 10 days each month)
Number of subjects: 72
Study 7750020 — intervention group
Group type: COMPARATOR
Intervention: Elemental calcium (500 mg for 10 days each month)
Number of subjects: 72
Study 7750020 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin
Number of subjects: 72
Study 2105985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 2% gel
Number of subjects: 37
Study 2105985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 2105985 — intervention group
Group type: EXPERIMENTAL
Intervention: Etofenamate
Number of subjects: 37
Study 7041813 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid, 1 g daily (21 cases)
Number of subjects: 33
Study 7041813 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole, 1 g every 6 h (12 cases)
Number of subjects: 33
Study 31663620 — intervention group
Group type: EXPERIMENTAL
Intervention: DOX–MNPs treatment
Number of subjects: 0
Study 31663620 — intervention group
Group type: EXPERIMENTAL
Intervention: Avasimibe combined with DOX–MNPs treatment
Number of subjects: 0
Study 30842881 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory Community-Based Health Information System (PCBHIS)
Number of subjects: 10
Study 30842881 — intervention group
Group type: COMPARATOR
Intervention: Comparison area (no PCBHIS)
Number of subjects: 10
Study 28009106 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (high dose 1010 CFU/d)
Number of subjects: 46
Study 28009106 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (low dose 108 CFU/d)
Number of subjects: 46
Study 28009106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 25591799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib 0.5 mg with mFOLFOX-6
Number of subjects: 30
Study 25591799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib 1.5 mg with mFOLFOX-6
Number of subjects: 30
Study 25591799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib with mFOLFOX-6
Number of subjects: 30
Study 25618969 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng capsules (XFC)
Number of subjects: 120
Study 25618969 — intervention group
Group type: COMPARATOR
Intervention: Salazopyrin
Number of subjects: 120
Study 25618969 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 120
Study 21094015 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based module
Number of subjects: 141
Study 21094015 — intervention group
Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 141
Study 19785675 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in depression for intervention pharmacists
Number of subjects: 32
Study 19785675 — intervention group
Group type: COMPARATOR
Intervention: Usual care for control pharmacists
Number of subjects: 32
Study 19785675 — intervention group
Group type: EXPERIMENTAL
Intervention: General outcomes for all pharmacists
Number of subjects: 32
Study 20888887 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine spray
Number of subjects: 84
Study 20888887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 16299430 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Status Indicators (FSI)
Number of subjects: 6465
Study 16299430 — intervention group
Group type: COMPARATOR
Intervention: Comorbidity indices
Number of subjects: 6465
Study 12117024 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple ligation
Number of subjects: 109
Study 12117024 — intervention group
Group type: COMPARATOR
Intervention: Single ligation
Number of subjects: 109
Study 10430010 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol-releasing vaginal ring
Number of subjects: 303
Study 10430010 — intervention group
Group type: COMPARATOR
Intervention: Estriol suppositories
Number of subjects: 303
Study 10430010 — intervention group
Group type: COMPARATOR
Intervention: Placebo ring
Number of subjects: 303
Study 8520033 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg b.i.d. per os)
Number of subjects: 120
Study 8520033 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole (100 mg b.i.d. per os)
Number of subjects: 120
Study 2097908 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.35 mg/kg (Group B)
Number of subjects: 80
Study 2097908 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.45 mg/kg (Group C)
Number of subjects: 80
Study 2097908 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study 7439520 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium fusidate ointment
Number of subjects: 101
Study 7439520 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% fusidic acid cream
Number of subjects: 101
Study 27341089 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Optix Aqua MFCL
Number of subjects: 40
Study 27341089 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Optix Aqua SV
Number of subjects: 40
Study 27341089 — intervention group
Group type: EXPERIMENTAL
Intervention: PureVision MFCL
Number of subjects: 40
Study 27341089 — intervention group
Group type: EXPERIMENTAL
Intervention: Proclear D (center-distance MFCL)
Number of subjects: 40
Study 27341089 — intervention group
Group type: COMPARATOR
Intervention: Single-Vision (SV) lens
Number of subjects: 40
Study 27341089 — intervention group
Group type: EXPERIMENTAL
Intervention: All lens types
Number of subjects: 40
Study 27216274 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine and rituximab
Number of subjects: 561
Study 27216274 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine, cyclophosphamide, and rituximab
Number of subjects: 561
Study 23991719 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecolic duodenojejunostomy (A group, n = 58)
Number of subjects: 116
Study 23991719 — intervention group
Group type: COMPARATOR
Intervention: Vertical retrocolic duodenojejunostomy (VR group, n = 58)
Number of subjects: 116
Study 23991719 — intervention group
Group type: COMPARATOR
Intervention: Vertical retrocolic duodenojejunostomy (VR group)
Number of subjects: 116
Study 23991719 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecolic duodenojejunostomy (A group)
Number of subjects: 116
Study 22082301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 46)
Number of subjects: 94
Study 22082301 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 48)
Number of subjects: 94
Study 20361381 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric granule formulation of artesunate-mefloquine
Number of subjects: 71
Study 20361381 — intervention group
Group type: COMPARATOR
Intervention: Co-blister tablet formulation
Number of subjects: 71
Study 18721455 — intervention group
Group type: EXPERIMENTAL
Intervention: Early shockroom CT scanning
Number of subjects: 1124
Study 18721455 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic imaging strategy
Number of subjects: 1124
Study 16356228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (blood glucose between 80 and 110 mg/dl)
Number of subjects: 0
Study 16356228 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (blood glucose less than 200 mg/dl)
Number of subjects: 0
Study 12421159 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen (HBO treatment)
Number of subjects: 16
Study 12421159 — intervention group
Group type: COMPARATOR
Intervention: 10% oxygen in nitrogen (hyperbaric normoxic placebo = sham treatment)
Number of subjects: 16
Study 10601381 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days, n = 19,939)
Number of subjects: 39876
Study 10601381 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 19,937)
Number of subjects: 39876
Study 10601381 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days)
Number of subjects: 39876
Study 10601381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study 10601381 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days) among smokers
Number of subjects: 39876
Study 10601381 — intervention group
Group type: COMPARATOR
Intervention: Placebo among smokers
Number of subjects: 39876
Study 7723496 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.85% carmustine polymer discs
Number of subjects: 222
Study 7723496 — intervention group
Group type: COMPARATOR
Intervention: Placebo polymer discs
Number of subjects: 222
Study 2104115 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination offered through a questionnaire (first period)
Number of subjects: 298
Study 2104115 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination offered without questionnaire (second period)
Number of subjects: 298
Study 2104115 — intervention group
Group type: COMPARATOR
Intervention: Control group (third period)
Number of subjects: 298
Study 6996113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (60 mg elemental iron)
Number of subjects: 101